Literature DB >> 21993076

Antibody response in MOG(35-55) induced EAE.

Patrice H Lalive1, Nicolas Molnarfi, Mahdia Benkhoucha, Martin S Weber, Marie-Laure Santiago-Raber.   

Abstract

Neurological deficit in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis is widely considered to be a consequence of synergistic T and B cell responses to central nervous system (CNS) antigens. We show that mice immunized with encephalitogenic myelin oligodendrocyte glycoprotein (MOG(35-55)) peptide develop significant serum levels of anti-MOG antibodies in parallel with disease progression. Furthermore, EAE mice developed antibodies against DNA and RNA, a serological hallmark observed in autoimmune diseases such as systemic lupus erythematosus. The presence of anti-nucleic responsive B cells and antibodies during EAE may highlight a previously unappreciated mechanism in the pathogenesis of CNS autoimmunity.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993076     DOI: 10.1016/j.jneuroim.2011.09.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  20 in total

Review 1.  Origins and significance of astrogliosis in the multiple sclerosis model, MOG peptide EAE.

Authors:  Monica Moreno; Fuzheng Guo; Emily Mills Ko; Peter Bannerman; Athena Soulika; David Pleasure
Journal:  J Neurol Sci       Date:  2013-01-05       Impact factor: 3.181

2.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

3.  Dependency of Experimental Autoimmune Encephalomyelitis Induction on MOG35-55 Properties Modulating Matrix Metalloproteinase-9 and Interleukin-6.

Authors:  Ji-Eun Seo; Mahbub Hasan; Joon-Seung Han; Nak-Kyoon Kim; Ji Eun Lee; Kang Mi Lee; Ju-Hyung Park; Ho Jun Kim; Junghyun Son; Jaeick Lee; Oh-Seung Kwon
Journal:  Neurochem Res       Date:  2015-10-13       Impact factor: 3.996

Review 4.  B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Authors:  Silke Kinzel; Martin S Weber
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 5.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

6.  Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis.

Authors:  Eduardo Huarte; SangMu Jun; Agnieszka Rynda-Apple; Sara Golden; Larissa Jackiw; Carol Hoffman; Massimo Maddaloni; David W Pascual
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

7.  In trans T cell tolerance exacerbates experimental allergic encephalomyelitis by interfering with protective antibody responses.

Authors:  Jason A Cascio; Marie-Therese Khairallah; Xiaoxiao Wan; Weirong Chen; Linda M Rowland; Mermagya Dhakal; Mindy M Miller; Habib Zaghouani
Journal:  J Neuroimmunol       Date:  2013-10-05       Impact factor: 3.478

8.  RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation.

Authors:  Sitao Zhang; Yaning Su; Zhengxin Ying; Dejia Guo; Chenjie Pan; Jia Guo; Ziye Zou; Lei Wang; Ze Zhang; Zhaodi Jiang; Zhiyuan Zhang; Xiaodong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-05       Impact factor: 11.205

9.  In vitro effect of human serum and fetal calf serum on CD4+ T cells proliferation in response to myelin oligodendrocyte glycoprotein (MOG) in correlation with RBP/TTR ratio in multiple sclerotic patients.

Authors:  Niyaz Mohammadzadeh Honarvar; Mohammad Hossein Harrirchian; Fariba Koohdani; Fereydoon Siassi; Sima Jafari Rad; Mina Abdolahi; Sama Bitarafan; Eisa Salehi; Mohammad Ali Sahraian; Mohammad Reza Eshraghian; Ali Akbar Saboor-Yarghi
Journal:  J Mol Neurosci       Date:  2013-04-06       Impact factor: 3.444

10.  Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain.

Authors:  Andrew J Kwilasz; Suzanne M Green Fulgham; Julissa Chante Duran-Malle; Anouk E W Schrama; Eric H Mitten; Laurel S Todd; Hardik P Patel; Tracey A Larson; Madison A Clements; Kevin M Harris; Scott T Litwiler; Lewis O Harvey; Steven F Maier; Raymond A Chavez; Kenner C Rice; Anne-Marie Van Dam; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2021-01-07       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.